Early, Aggressive LDL Cholesterol⁢ Lowering Key to Heart Health

‍ Updated June 01, 2025

miami,⁣ Fla. — early⁤ and sustained reduction of low-density lipoprotein cholesterol (LDL-C) is⁣ critical in preventing atherosclerotic cardiovascular disease (ASCVD). That’s according to Kausik K. Ray, MD, speaking at the 2025 National Lipid Association (NLA) Scientific Sessions.

Ray, a professor at imperial College London, emphasized that initiating LDL-C lowering therapies early and ⁢ensuring long-term adherence leads to a greater reduction in major adverse cardiovascular⁣ events ⁣(MACE). The benefits are seen regardless of the specific lipid-lowering agent used.

while high cholesterol is often the⁢ diagnostic focus, Ray noted that the underlying issue is cholesterol retention in the arterial wall. Since LDL particles ‍comprise about 90% of circulating apolipoprotein B (apoB)-containing particles, LDL-C remains the primary target for ASCVD prevention. Even slightly elevated LDL-C can speed up plaque formation, especially in those with diabetes, hypertension, or arterial damage‍ from smoking.

Various strategies, including statins,⁣ ezetimibe, bempedoic acid, PCSK9 inhibitors, and siRNA agents, enhance LDL receptor activity, increasing LDL clearance. Statins and bempedoic acid reduce cholesterol synthesis in the liver, while ezetimibe ⁤and dietary changes reduce cholesterol absorption in the intestine. PCSK9 inhibitors and siRNA therapies prolong LDL receptor lifespan, allowing for sustained LDL-C clearance.

Ray highlighted the consistent benefits across different lipid-lowering therapies. ‍Trials like ODYSSEY Outcomes and FOURIER have shown that each 1⁤ mmol/L (38.7 mg/dL) reduction in LDL-C corresponds to a relative risk reduction in ⁤MACE. The CLEAR Outcomes trial further supported these findings, demonstrating that LDL-C reductions achieved⁣ through ATP-citrate lyase⁣ inhibition resulted in similar risk reductions to ⁤those seen in statin and PCSK9 inhibitor studies.

Data from simulation models and registry studies underscore the importance of treatment timing. Analyses from the SWEDEHEART registry indicate that initiating high-intensity statins and combination therapy within 12 weeks of an acute myocardial infarction significantly reduces MACE compared to⁢ delayed intensification. Delaying LDL-C target achievement can result in persistent excess risk, even with later intensification of therapy.

“About a month ago,we published this data from SWEDEHEART essentially trying to simulate a trial where you‍ give statins and ezetimibe early after myocardial infarction within 12 weeks,or you ⁣give them the medication on combination therapy between 12 weeks,16 months,or never,” Ray‍ said during the NLA presentation. “You can never ethically do a trial where you⁣ delay an ‍intervention that you’ve already got data ⁢for.So,this is the closest we’re ever going to get to trial evidence,if you will.”

Ray explained that these findings have significant public health implications for optimizing LDL-C management. Modeling data suggest that global early combination therapy ⁣could prevent thousands of MACE events annually. These findings reinforce the need for system-level changes in care pathways ⁤and interventions focused on implementing guideline-directed therapy effectively.

“If you change your care pathway, and⁤ rather of a stepwise approach, you just [adopt a] standard of care [in which you] give people a high intensity statin and ezetimibe, for a population of 35,000, there will be 477 fewer events,” Ray said. “But for a country like the US,where there’s probably‍ a quarter of a million myocardial infarctions per year,the number of events you’re going to get over 3 years is 17,934 events,meaning in 3 years,that⁣ policy change⁤ alone⁣ is going to prevent about 3000⁢ MACE events.”

What’s⁣ next

future research should focus on implementing strategies for early and aggressive LDL-C lowering in routine clinical practise to improve patient outcomes and reduce‍ the burden of ASCVD.